{
  "ticker": "LLY",
  "timestamp": "2025-12-01T08:40:19.710333",
  "analysis_date": "2025-06-06",
  "historical_mode": true,
  "portfolio_value": 100000.0,
  "verdict": "MODIFY",
  "final_position_pct": 0.042058,
  "final_position_dollars": 4205.77,
  "confidence": "LOW",
  "reasoning": "The decision to modify our position in Eli Lilly (LLY) to 4.21% is strategically sound, given the current market conditions and the company's potential resilience. While the bear thesis highlights concerns around high valuation metrics and trading volume, the overall market sentiment and our position size allow us to capitalize on any upside while maintaining prudent risk management. This adjustment strikes a balance between opportunity and caution, aligning with our portfolio objectives.",
  "key_factors": [
    "High valuation metrics",
    "Weak trading volume",
    "Proximity to resistance levels"
  ],
  "conditions": [
    "Market sentiment remains stable",
    "No significant catalysts identified"
  ],
  "stop_loss_pct": 15,
  "profit_targets": [
    12.5,
    18.8,
    25
  ],
  "guardrail_corrections": [],
  "is_llm_decision": true,
  "risk_controls": {
    "stop_loss": {
      "percentage": 15,
      "dollar_amount": 630.87
    },
    "take_profit": {
      "targets": [
        12.5,
        18.8,
        25
      ],
      "scale_out": [
        0.33,
        0.33,
        0.34
      ]
    },
    "time_limit": {
      "max_holding_period": "90 days",
      "review_frequency": "weekly"
    }
  },
  "risk_consensus": {
    "stances": {
      "aggressive": "HOLD",
      "neutral": "SMALL BUY",
      "conservative": "AVOID"
    },
    "position_sizes": {
      "aggressive": 3.5000000000000004,
      "neutral": 0,
      "conservative": 0
    },
    "agreements": [],
    "conflicts": [
      "Mixed views: 1 buy, 1 avoid"
    ],
    "avg_position_size": 0.011666666666666667,
    "red_flags": [
      {
        "flag": "Analysis failed",
        "severity": "HIGH",
        "source": "System"
      }
    ]
  },
  "position_sizing": {
    "range_min_pct": 3.5,
    "range_max_pct": 5.0,
    "final_pct": 4.2058,
    "final_dollars": 4205.77
  },
  "agent_votes": {
    "bullish": 1,
    "bearish": 1,
    "neutral": 2,
    "consensus": "SPLIT"
  },
  "research_recommendation": "HOLD",
  "report": "\n======================================================================\nRISK MANAGER FINAL DECISION: LLY\n======================================================================\n**Analysis Date:** 2025-06-06 (HISTORICAL)\n**Portfolio:** $100,000\n\n## VERDICT: MODIFY\n**Position:** 4.21% ($4,205.77)\n**Confidence:** LOW\n\n## REASONING\nThe decision to modify our position in Eli Lilly (LLY) to 4.21% is strategically sound, given the current market conditions and the company's potential resilience. While the bear thesis highlights concerns around high valuation metrics and trading volume, the overall market sentiment and our position size allow us to capitalize on any upside while maintaining prudent risk management. This adjustment strikes a balance between opportunity and caution, aligning with our portfolio objectives.\n\n## KEY FACTORS\n\u2022 High valuation metrics\n\u2022 Weak trading volume\n\u2022 Proximity to resistance levels\n\n## EVALUATOR SUMMARY\n- Aggressive: HOLD @ 3.5%\n- Neutral: SMALL BUY @ 0%\n- Conservative: AVOID @ 0%\n\n## AGENT CONSENSUS\n- Bullish Votes: 1/4\n- Bearish Votes: 1/4\n- Neutral Votes: 2/4\n- Overall: Split\n\n## POSITION SIZING\n- Range: 3.5% - 5.0%\n- Final: 4.21% ($4,205.77)\n\n## RISK CONTROLS\n- Stop Loss: -15%\n- Profit Targets: +12.5%, +18.8%, +25%\n\n## CONDITIONS\n\u2022 Market sentiment remains stable\n\u2022 No significant catalysts identified\n\n======================================================================\n"
}